Followers | 751 |
Posts | 16573 |
Boards Moderated | 0 |
Alias Born | 05/30/2007 |
Thursday, November 10, 2022 2:38:33 PM
LIGAND EARNS $6.5 MILLION MILESTONE PAYMENT FROM ROCHE
April 20, 2010
Roche Advances RG7348 into Clinical Development for Hepatitis C
SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it earned a $6.5 million payment from Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral (HCV) infection. The milestone payment arises from a 2008 collaboration and license agreement between Roche and Metabasis Therapeutics, Inc. Ligand acquired Metabasis in January 2010. Ligand's net proceeds from the milestone payment will be approximately $2.3 million after paying $4.2 million to others including holders of the Ligand-issued "Roche" CVR.
"This is a great milestone for Ligand due to the cash revenue and because it validates the quality of assets we assumed through our recent acquisitions," said John L. Higgins, President and Chief Executive Officer of Ligand. "Recently we have acquired three public companies that have contributed a vast array of partnered and pipeline assets. We are very pleased with our partnership with Roche and are excited to see their program advance to human development for HCV."
Under the 2008 collaboration and license agreement, Metabasis contributed HepDirect(R) liver-targeting technology to help develop prodrugs of Roche's proprietary lead nucleosides against HCV infection. Ligand is eligible to receive additional payments from Roche upon the achievement of certain further development and regulatory milestones as well as royalties on potential sales of the drug, subject to obligations to share such payments with holders of the Ligand-issued Roche CVR.
The CVRs
Ligand issued a Roche contingent value right (CVR) to each former holder of a Metabasis common share as part of Ligand's acquisition of Metabasis. Each Roche CVR entitles holders to certain payments if and when Ligand receives certain payments in connection with the Roche-Metabasis collaboration and license agreement. Of the $6.5 million milestone payment, 65% is earmarked for the Roche CVR holders. After reduction for pre-existing contractual payment obligations, the Roche CVR holders will receive approximately $2.7 million in respect of this milestone payment.
About Ligand Pharmaceuticals
Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's, inflammatory diseases, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Bristol-Myers Squibb, and Cephalon and more than 30 programs are in various stages of development by its partners.
Link: https://investor.ligand.com/press-releases/detail/44/ligand-earns-6-5-million-milestone-payment-from-roche
Recent LGND News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 06:27:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:28:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 11:12:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/01/2024 09:09:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:49:56 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:49:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 11:05:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 10:43:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:24:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:10:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:10:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:10:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:10:16 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 11:26:25 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 08:39:23 PM
- Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene • GlobeNewswire Inc. • 01/11/2024 12:30:00 AM
- Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment • Dow Jones News • 01/05/2024 10:40:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:07:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:07:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 08:27:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 08:27:13 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM